Deborah, former chair of the firm's Biotechnology & Chemical Practice Group, has in-depth experience in technical areas, such as biotechnology, pharmaceuticals, molecular biology, analytical instruments, agrochemicals, and clean technology.

Deborah Sterling, Ph.D.

Director

dsterling@sternekessler.com
+1 202.772.8501
LinkedIn

Overview

Deborah Sterling, Ph.D., is a director in Sterne Kessler’s Biotechnology & Chemical Practice Group and was the group’s former chair from 2018-2023. Her practice is focused on the biotechnology and pharmaceutical industries, where she counsels clients from around the world in all areas of patent procurement, including domestic and foreign patent preparation, and lifecycle management strategies. Her practice also includes counseling clients on intellectual property strategy, including freedom-to-operate and patentability issues, validity and infringement issues, and due diligence investigations in connection with acquisitions and investments.

Deborah’s experience includes representing clients in over 75 post-grant proceedings and multiple patent interferences and reexaminations. She has also been involved in multiple pharmaceutical and biotechnology patent litigations, including those brought under the Hatch-Waxman Act. Deborah leverages her experience in inter partes disputes to help patent owners craft and execute patent strategies that best align with their business needs.

Deborah’s intellectual property experience has been principally in technical areas such as biotechnology, pharmaceuticals, molecular biology, analytical instruments, agrochemicals, and clean technology. She also counsels clients in emerging and regulated industries, including cannabinoid therapeutics.

She has been recognized numerous times as a leading practitioner in the life sciences. Managing IP has named her an “IP Star” 2020-2023; the IAM Patent 1000 has ranked her among the top Washington, D.C. patent prosecution attorneys 2021-2023; and World Intellectual Property Review (WIPR) has listed her as a “WIPR Leader” 2023 – 2022. LMG Life Sciences named her a “Life Sciences Star” every year from 2019-2023. LMG Life Sciences also honored her as the “Patent Strategy Attorney of the Year (DC Metro)” in 2021, listed her as a finalist for “Patent Strategy Attorney of the Year (DC Metro)” in 2023, and a finalist for “Post Grant Proceeding Attorney of the Year” in 2020. DCA Live has also recognized her as an “Emerging Women Leaders in Law” (2019) and by Profiles in Diversity Journal as a “Women Worth Watching” (2019).

Deborah is a contributing author of Patent Office Litigation, Second Edition, published in 2017, and the two-volume set Patent Office Litigation, published in 2012 by Thomson Reuters Westlaw. She is also a contributing author of the “Patentability Challenges at the U.S. Patent and Trademark Office” chapter in the Patent Litigation Strategies Handbook, 4th ed., published by the ABA in 2015, and authored a chapter of U.S. Chemical Patent Law: A Practical Guide, published by Bloomberg Law.

Deborah was previously the Chairperson of the firm’s Professional Development Committee.

Deborah earned her J.D. from George Mason University School of Law, her Ph.D. in molecular and cellular physiology from the University of Alberta, and her B.S., with first-class honours, in biochemistry from Heriot-Watt University.

Related Services

Related Industries

Representative Matters

District Court

  • Carestream Health, Inc. v. Caliper Life Sciences, Inc. – W.D.Wis. – (favorable settlement for our client Caliper)
  • Caliper Life Sciences, Inc., et al. v. Carestream Health, Inc. – N.D.Cal. – (favorable settlement for our client Caliper)
  • Jazz Pharmaceuticals v. Amneal Pharmaceuticals – D.N.J. – (ANDA case: Xyrem)
  • Reckitt Benckiser LLC, et al v. Amneal Pharmaceuticals, LLC – D. NJ. (ANDA case: Delsym)

International Trade Commission

  • In re Lithium Silicate Materials and Products Containing the Same, ITC Investigation No 337-TA-911; represented complainant Ivoclar Vivadent

Arbitration

  • Caliper Life Sciences, Inc. v. Fluidigm Corporation (arbitration)

Court of Appeals for the Federal Circuit

  • 15-1317, In re: Gevo, Inc.: Appeal by Patent Owner of PTAB Final Written Decision in Inter Partes Review cancelling all claims; We represented Petitioner Butamax Advanced Biofuels in the IPR; PTAB Decision affirmed
  • 15-1824, Eveready Battery Co., Inc. v. Spectrum Brands, Inc.: Appeal by Patent Owner of PTAB Final Written Decision in Inter Partes Reexamination cancelling all claims; We represented Requester in the reexam; PTAB Decision affirmed
  • 18-1770, -1771, Ansell Healthcare Products LLC v. Iancu: Appeals by Patent Owner of PTAB Final Written Decisions in Inter Partes Reviews cancelling all claims; We represented Patent Owner in the IPRs; appeals dismissed
  • 18-1957, Creative Spark, LLC v. Kingsford Products Company: Appeal by Patent Owner of PTAB Final Written Decision in Inter Partes Review cancelling most claims; We represented Petitioner in the IPR; PTAB Decision affirmed
  • 20-1747, -1748, -1749, -1750, -1751, -1752, Teva Pharmaceuticals v. Eli Lilly and Co.: Appeals by Patent Owner of PTAB Final Written Decisions in Inter Partes Reviews cancelling all claims; We represented Patent Owner in the IPRs; Appeals pending
  • 20-1876, -1877, -1878, Eli Lilly and Co. v. Teva Pharmaceuticals: Appeals by Petitioner of PTAB Final Written Decisions in Inter Partes Reviews upholding all claims; We represented Patent Owner in the IPRs; Appeals pending

Post-Grant Proceedings

Petitioner:

  • PGR2019-00048: Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc.
  • IPR2019-00741: Amgen, Inc. v. Alexion Pharmaceuticals, Inc.
  • IPR2019-00740: Amgen Inc. v. Alexion Pharmaceuticals, Inc.
  • IPR2019-00739: Amgen Inc. v. Alexion Pharmaceuticals, Inc.
  • IPR2018-01370: Thermo Fisher Scientific Inc. et al v. The Regents of the University of California
  • IPR2018-01369: Thermo Fisher Scientific Inc. et al v. The Regents of the University of California
  • IPR2018-01368: Thermo Fisher Scientific Inc. et al v. The Regents of the University of California
  • IPR2018-01367: Thermo Fisher Scientific Inc. et al v. The Regents of the University of California
  • IPR2018-01347: Thermo Fisher Scientific Inc. et al v. The Regents of the University of California
  • IPR2018-01156: Thermo Fisher Scientific Inc. et al v. The Regents of the University of California
  • PGR2017-00034: Concert Pharmaceuticals, Inc. v. Incyte Corporation
  • IPR2016-01831: The Kingsford Products Company, LLC v. Creative Spark LLC
  • IPR2016-01608: BioEQ IP AG v. Genentech, Inc.
  • IPR2016-01582: Wockhardt Bio AG v. Janssen Oncology, Inc.
  • IPR2016-00678: IntelGenX Corp. v ICOS Corp.
  • IPR2016-00370: Wockhardt Bio AG. v. Jazz Pharmaceuticals, Inc.
  • IPR2015-01560: 10X Genomics, Inc. v. The University of Chicago
  • IPR2015-01558: 10X Genomics, Inc. v. RainDance Technologies, Inc.
  • IPR2015-01163: 10X Genomics, Inc. v. The University of Chicago
  • IPR2015-01162: 10X Genomics, Inc. v. The University of Chicago
  • IPR2015-01158: 10X Genomics, Inc. v. The University of Chicago
  • IPR2015-01157: 10X Genomics, Inc. v. The University of Chicago
  • IPR2015-01156: 10X Genomics, Inc. v. The University of Chicago
  • IPR2015-00547: Amneal Pharms. LLC, Par Pharms., Inc. v. Jazz Pharms., Inc.
  • IPR2015-00546: Amneal Pharms. LLC, Par Pharms., Inc. v. Jazz Pharms., Inc.
  • IPR2015-00545: Amneal Pharms. LLC, Par Pharms., Inc. v. Jazz Pharms., Inc.
  • IPR2015-00154: BioReference Labs., Inc.; GeneDx, Inc. v. Univ. Utah Research Found.
  • IPR2015-00152: BioReference Labs., Inc.; GeneDx, Inc. v. Univ. Utah Research Found.
  • IPR2014-01316: BioReference Labs., Inc.; GeneDx, Inc. v. Univ. Utah Research Found.
  • IPR2014-01315: BioReference Labs., Inc.; GeneDx, Inc. v. Myriad Genetics
  • IPR2014-01314: BioReference Labs., Inc.; GeneDx, Inc. v. Myriad Genetics
  • IPR2014-01313: BioReference Labs., Inc.; GeneDx, Inc. v. Myriad Genetics
  • IPR2014-01312: BioReference Labs., Inc.; GeneDx, Inc. v. Myriad Genetics
  • IPR2014-01311: BioReference Labs., Inc.; GeneDx, Inc. v. Univ. Utah Research Found.
  • IPR2014-01310: BioReference Labs., Inc.; GeneDx, Inc. v. Myriad Genetics
  • IPR2014-01301: BioReference Labs., Inc.; GeneDx, Inc. v. Myriad Genetics
  • IPR2014-01299: BioReference Labs., Inc.; GeneDx, Inc. v. Myriad Genetics
  • IPR2014-01298: BioReference Labs., Inc.; GeneDx, Inc. v. Myriad Genetics
  • IPR2014-01296: BioReference Labs., Inc.; GeneDx, Inc. v. Myriad Genetics
  • IPR2014-00876: Apotex Corp. v. VIIV Healthcare UK Limited
  • IPR2014-00581: Butamax Advanced Biofuels, LLC v. Gevo Inc.
  • IPR2014-00402: Butamax Advanced Biofuels, LLC v. Gevo Inc.
  • IPR2014-00250: Butamax Advanced Biofuels, LLC v. Gevo Inc.
  • IPR2014-00144: Butamax Advanced Biofuels, LLC v. Gevo Inc.
  • IPR2014-00143: Butamax Advanced Biofuels, LLC v. Gevo Inc.
  • IPR2014-00142: Butamax Advanced Biofuels, LLC v. Gevo Inc.
  • IPR2013-00539: Butamax Advanced Biofuels, LLC v. Gevo Inc.
  • IPR2013-00215: Butamax Advanced Biofuels, LLC v. Gevo Inc.
  • IPR2013-00214: Butamax Advanced Biofuels, LLC v. Gevo Inc.
  • CBM2014-00150: Amneal Pharms. LLC, et al. v. Jazz Pharms., Inc.
  • CBM2014-00149: Amneal Pharms. LLC, et al. v. Jazz Pharms., Inc.

Patent Owner:

  • IPR2018-01712: Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
  • IPR2018-01711: Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
  • IPR2018-01710: Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
  • IPR2018-01427: Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
  • IPR2018-01426: Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
  • IPR2018-01425: Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
  • IPR2018-01424: Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
  • IPR2018-01423: Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
  • IPR2018-01422: Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
  • IPR2018-00431: Forty Seven, Inc. v. Stichting Sanquin Bloedvoorziening
  • PGR2017-00018: BAYER CROPSCIENCE LP v. Exosect Limited
  • IPR2017-00807: Argentum Pharmaceuticals LLC et al v. Cipla Limited
  • IPR2017-00066: Reckitt Benckiser LLC v. Ansell Healthcare Products LLC
  • IPR2017-00063: Reckitt Benckiser LLC v. Ansell Healthcare Products LLC
  • IPR2016-01893: Kaz USA, Inc. v. Brita LP
  • IPR2016-01530: Forty Seven Inc. v. Stichting Sanquin Bloedvoorziening
  • IPR2016-01529: Forty Seven Inc. v. Stichting Sanquin Bloedvoorziening
  • IPR2016-00441: Aerospace Comms. Holdings Co., Ltd. v. IDQ Operating, Inc.
  • IPR2016-00442: Aerospace Comms. Holdings Co., Ltd. v. IDQ Operating, Inc.
  • IPR2012-00022: Ariosa Diagnostics v. Isis Innovation Limited.

Accolades

  • IAM Patent 1000, “Washington, DC: Recommended – Patent Prosecution” (2023 – 2021)
  • LMG Life Sciences, “Finalist – Patent Strategy Attorney of the Year (DC Metro)” (2023)
  • World Intellectual Property Review (WIPR), “WIPR Leaders” (2023 – 2022)
  • Managing IP, “IP Star” (2023 – 2020)
  • LMG Life Sciences, “Patent Strategy Attorney of the Year (DC Metro)” (2021)
  • PTAB Bar Association, “Top 50 Women in PTAB Trials” (2021 & 2019)
  • LMG Life Sciences, “Life Sciences Star” (2023 – 2019)
  • LMG Life Sciences, “Finalist – Post-Grant Proceedings Attorney of the Year” (2020)
  • Profiles in Diversity Journal, “Women Worth Watching®” (2019)
  • DCA Live, “Emerging Women Leaders in Law” (2019)
  • Lawyer Monthly, “Women in Law Award – Biotechnology Category” (2016-2015)
  • Corporate LiveWire, “Biotechnology Lawyer of the Year – Washington, D.C.” (2015)
  • Super Lawyers, “Super Lawyer – Washington, DC” (2024)

Education

  • J.D., George Mason University Antonin Scalia Law School
  • Ph.D., Molecular and Cellular Physiology, University of Alberta
  • B.Sc., Biochemistry, Heriot-Watt University, first-class honours

Admissions

  • District of Columbia
  • New York
  • Supreme Court of the United States
  • U.S. Court of Appeals for the Federal Circuit
  • U.S. District Court for the District of Columbia
  • United States Patent & Trademark Office

Events

Speaking Engagement 10th LSX World Congress London, UK, April 29, 2024
Speaking Engagement FDA and PTO Panel Colorado Springs, CO, July 1, 2023
Speaking Engagement Successfully Claiming Antibody Patents in Europe and the U.S.: Incorporating Takeaways From the Latest Case Law Into Your Prosecution Strategy Amsterdam, the Netherlands, May 24, 2023
Speaking Engagement 2023 Focus on Pharma Washington, DC, April 14, 2023
Speaking Engagement Written Description Enablement After Juno v. Kite London, England, November 29, 2022
Speaking Engagement Mitigating IP Risks In Business Transactions Virtual, December 7, 2021
Speaking Engagement Evolving Strategies in View of Discretionary Denial Washington, DC, September 23, 2021
Speaking Engagement Strategic Business Deals: Building a Best in Class IP Litigation Strategy Virtual, June 8, 2021
Speaking Engagement The Trial: Stop Spinning Your Wheels & Start Winning Virtual, April 21, 2021
Webinar JETRO New York Intellectual Property Group Seminar April 15, 2021
Speaking Engagement Strategic Updates for Managing your Litigation Strategy Virtual, February 24, 2021
Speaking Engagement Protecting Cannabis Intellectual Property Virtual, November 16, 2020
Webinar Protecting Cannabis IP: Viability of Cannabis Patents, USPTO Guidance on Trademark Applications, Copyrights October 27, 2020
Speaking Engagement Never Tell Me the Odds: Trial Strategy Virtual, September 23, 2020
Webinar Protecting Cannabis IP: Viability of Cannabis Patents, New USPTO Guide on Trademark Applications for Cannabis, Copyrights October 15, 2019
Speaking Engagement USPTO Post-Grant Patent Trials 2019: New Challenges & Tactics New York, NY, September 11, 2019
Webinar Protecting Cannabis IP: Viability of Cannabis Patents, New USPTO Guide on Trademark Applications for Cannabis, Copyrights August 20, 2019
Webinar The Post-SAS/Oil States PTAB Landscape: A Synthesis of the Most Important Emerging Information May 11, 2018
Speaking Engagement MIP Life Sciences Forum New York, NY, September 13, 2017
LES 2016 Annual Meeting October 23, 2016
Prosecution in Light of IPRs: Lessons Learned July 13, 2016
Organ-on-a-Chip World Congress 2016 July 7, 2016
2016 Materials Research Society Spring Meeting & Exhibit March 28, 2016
Patent Office Litigation: Lessons Learned February 24, 2016
3D Cellular Models Revitalizing Phenotypic Screening January 16, 2016
Lessons From Practicing at the PTAB January 14, 2016
International Women's Leadership Forum December 9, 2014
Forest Products Association of Canada Biopathways Partnership Network September 11, 2014
IP Counsel Exchange for Biosimilar Applicants and Sponsors January 23, 2014
2013 Intellectual Property Retreat - National Harbor September 19, 2013
Patent Litigation at the USPTO Under the America Invents Act of 2011 October 19, 2011

Related Resources From Deborah Sterling, Ph.D.

Press Release Eighteen Sterne Kessler Attorneys Recognized as 2024 “Super Lawyers” and “Rising Stars” Sterne, Kessler, Goldstein & Fox April 25, 2024
Press Release Sterne Kessler and 14 Directors Earn Top Rankings in Managing IP’s 2023 “IP Stars” Guide Sterne, Kessler, Goldstein & Fox July 6, 2023
Press Release Six Sterne Kessler Directors Distinguished by World Intellectual Property Review as 2023 WIPR Leaders Sterne, Kessler, Goldstein & Fox July 6, 2023
Press Release Firm and 18 Sterne Kessler Directors Earn Top Rankings in 2023 IAM Patent 1000 for World-Class Patent Work Sterne, Kessler, Goldstein & Fox June 26, 2023
In the News A Hazy Picture: The State of Play for Cannabis IP in 2023 Managing IP January 18, 2023
In the News The Three Developments Exciting US Patent Practitioners in 2023 Managing IP January 6, 2023
Press Release Sterne Kessler and Seven Directors Recognized in LMG Life Sciences Rankings for the 10th Consecutive Year Sterne, Kessler, Goldstein & Fox September 22, 2022
Firm Announcements Sterne Kessler Raises Over $34,000 for the Legal Aid Society of the District of Columbia Sterne, Kessler, Goldstein & Fox August 8, 2022
Press Release Sterne Kessler and 17 Directors Distinguished for Excellence in Patent Litigation and Prosecution in 2022 IAM Patent 1000 Sterne, Kessler, Goldstein & Fox July 12, 2022
Press Release Sterne Kessler and 14 Directors Earn Top Rankings for IP Litigation and Prosecution in Managing IP’s 2022 “IP Stars” Guide Sterne, Kessler, Goldstein & Fox July 5, 2022
Press Release Four Sterne Kessler Directors Named “WIPR Leaders” By World Intellectual Property Review Sterne, Kessler, Goldstein & Fox June 2, 2022
Press Release Deborah Sterling, Ph.D. and Michelle K. Holoubek Named to PTAB Bar Association’s Top 50 Women in PTAB Trials List Sterne, Kessler, Goldstein & Fox March 9, 2022
Press Release Sterne Kessler Publishes 2021 PTAB Year in Review: Analysis & Trends Report Sterne, Kessler, Goldstein & Fox March 7, 2022
In the News The Most-Read IP Law360 Guest Articles of 2021 Law360 December 23, 2021
Press Release Sterne Kessler and Seven Directors Earn Top-Tier Designations in 2021 LMG Life Sciences Rankings Sterne, Kessler, Goldstein & Fox September 29, 2021
Press Release Directors Ellison, Rozendaal, and Sterling Win Prominent LMG Life Sciences Americas Awards Sterne, Kessler, Goldstein & Fox September 23, 2021
In the News Fed. Circ. Axes Teva Antibody IP But Allows Treatment Patents Law360 August 16, 2021
In the News Teva Win on Three Migraine Drug Patents, Losses on Six Upheld Bloomberg Law August 16, 2021
Firm Announcements Sterne Kessler Raises over $25,000 for the Legal Aid Society of the District of Columbia fivejars August 5, 2021
Press Release Sterne, Kessler, Goldstein & Fox Earns 13 Market-Leading Awards for Excellence in the First Six Months of 2021 Sterne, Kessler, Goldstein & Fox July 26, 2021
Press Release Sterne, Kessler, Goldstein & Fox and 16 Directors Recognized for Excellence in 2021 IAM Patent 1000 Rankings Sterne, Kessler, Goldstein & Fox July 1, 2021
Press Release Sterne Kessler and 13 Directors Earn Top Rankings for IP Litigation and Prosecution in 2021 “IP Stars” Guide Sterne, Kessler, Goldstein & Fox June 17, 2021
Press Release Sterne Kessler Recognized as a “Top Tier” Patent Prosecution Firm by The Legal 500 Sterne, Kessler, Goldstein & Fox June 14, 2021
In the News Fed. Circ. Mulls Mixed PTAB Rulings In Teva Antibody IP Fight Law360 June 7, 2021
In the News Legal Industry News: Law Firm Hires, Recognition & Attorneys Getting Out the Vote National Law Review October 8, 2020
Press Release Firm and Seven Directors Recognized in 2020 LMG Life Sciences Rankings Sterne, Kessler, Goldstein & Fox P.L.L.C. October 6, 2020
Press Release Sterne, Kessler, Goldstein & Fox Wins Two 2020 LMG Life Sciences Americas Awards Sterne, Kessler, Goldstein & Fox P.L.L.C. September 24, 2020
In the News Amgen Drops Alexion Blood Drug IPRs, Gets 2025 License Law360 June 2, 2020
Press Release Sterne Kessler Ranked and 13 Directors Named “IP Stars” by Managing Intellectual Property Sterne, Kessler, Goldstein & Fox P.L.L.C. May 5, 2020
Press Release Sterne Kessler Again Receives Sole Band 1 Chambers Ranking for Patent Prosecution Among D.C. Firms Sterne, Kessler, Goldstein & Fox P.L.L.C. April 24, 2020
In the News PTAB Upholds 3 Teva Migraine Patents Challenged By Eli Lilly Law360 April 1, 2020
In the News Teva Gets PTAB To Review Cushing's Syndrome Drug Patent Law360 November 21, 2019
Press Release Longsworth and Sterling Distinguished as Women Worth Watching by Profiles in Diversity Journal fivejars October 3, 2019
Press Release Sterne Kessler Attorneys Author U.S. Chemical Patent Law Sterne, Kessler, Goldstein & Fox P.L.L.C October 1, 2019
Press Release Sterne Kessler and Directors Garner Highest Rankings in Annual LMG Life Sciences “Stars” Publication fivejars September 25, 2019
In the News Fed. Circ. Ruling Gives Patent Owners New Tool To Fight IPRs Law360 June 18, 2019
In the News Fed. Circ. Backs PTAB Ax Of J&J Prostate Cancer Drug Patent Law360 May 14, 2019
In the News Johnson & Johnson loses appeal to revive Zytiga patent Reuters May 14, 2019
In the News DCA Live’s Emerging Women Leaders in Law – Part 2 DCA Live March 19, 2019
In the News PTAB Practice Guide Changes Will Aid Patent Owners Law360 August 14, 2018
In the News Questions Surround Idea For PTAB Amendment ‘Off-Ramp’ Law360 July 24, 2017
In the News Global IP Strategies for Procuring and Protecting Green Innovations: A Focus on Europe, Brazil, China, and the US 25th Edition: European Biomass Conference and Exhibition June 12, 2017
In the News The Vault Practice Perspectives: Vault's Guide to Legal Practice Areas 2016 The Vault July 6, 2016
In the News 4 Things to Know About PGRs After 1st-Ever Final Decisions Law360 June 15, 2016
In the News Patent Office Issues First Post-Grant Review Decisions Bloomberg BNA's Patent, Trademark & Copyright Journal June 13, 2016
In the News Fed. Circ. Says PTAB Correctly Axed Eveready Battery Patent Law360 May 31, 2016
Press Release Four Sterne Kessler Attorneys Receive Lawyer Monthly Women in Law Award fivejars March 14, 2016
In the News Fed. Circ. Backs PTAB Ax Of Gevo Jet Fuel Patent Law360 February 16, 2016
Firm Announcements Claims Unpatentable for Obviousness in Final Written Decision IPR2014-00402 – Butamax Advanced Biofuels v. Gevo The National Law Review August 16, 2015
In the News PTAB Nixes Gevo Renewable Jet Fuel Patent In AIA Review Law360 March 16, 2015
In the News Legal Experts Assess Potential Impact of GeneDx's IPR Challenge of Myriad Patents GenomeWeb’s Pharmacogenomics Reporter August 27, 2014
In the News Defense to Myriad Patent Infringement Claim Now Moved to Patent Trial and Appeal Board Bloomberg BNA Patent, Trademark & Copyright Law Daily Bulletin August 20, 2014